ANI Pharmaceuticals (ANIP) Stock Trades Down, Here Is Why

Check out the companies making headlines yesterday:

OneMain : Consumer finance company OneMain Holdings fell by 5.1% on Monday after JP Morgan downgraded the stock to 'Underweight' from 'Neutral,' pointing to potential economic challenges for the company's customers. See our full article here.

Nextpower : Solar tracker company Nextpower rose by 8.2% on Monday after the company, formerly known as Nextracker, completed the formation of a joint venture in Saudi Arabia. See our full article here.

ANI Pharmaceuticals : Specialty pharmaceutical company ANI Pharmaceuticals rose by 13.6% on Monday after the company provided strong 2026 financial guidance that surpassed analyst expectations. See our full article here.

Akamai Technologies : Cloud technology company Akamai Technologies rose by 5.6% on Monday after Morgan Stanley upgraded the company's stock from 'Underweight' to 'Overweight' and raised its price target to $115 from $83. See our full article here.

Lemonade : Digital insurance provider Lemonade rose by 8.3% on Monday after Truist Securities initiated coverage on the company with a "Buy" rating and a $98 price target. See our full article here.

What Happened?

Shares of specialty pharmaceutical company ANI Pharmaceuticals jumped 13.6% in the afternoon session after the company provided strong 2026 financial guidance that surpassed analyst expectations. 

ANI projected total net revenues for 2026 to be between $1.055 billion and $1.115 billion. This forecast came in well above the FactSet consensus estimate of $955.1 million. A key driver for this expected growth was the company's rare disease treatment, Cortrophin Gel, which was projected to generate between $540 million and $575 million in revenue, a jump of 55% to 65% from 2025. The company also highlighted strong preliminary 2025 results for the drug, with its net revenues growing 76% from the previous year to $347.8 million. To support this momentum, ANI announced plans to expand its rare disease team by about 90 people.

The shares closed the day at $84.43, up 10.7% from previous close.

What Is The Market Telling Us

ANI Pharmaceuticals’s shares are not very volatile and have only had 8 moves greater than 5% over the last year. Moves this big are rare for ANI Pharmaceuticals and indicate this news significantly impacted the market’s perception of the business.

The biggest move we wrote about over the last year was 5 months ago when the stock gained 18.4% on the news that the company reported second-quarter earnings and revenue that surpassed analyst estimates and raised its full-year financial guidance. The specialty pharmaceutical company announced quarterly net revenues of $211.4 million, a 53.1% year-over-year increase that beat analyst estimates of $191.5 million. Adjusted earnings per share came in at $1.80, also significantly higher than the consensus forecast of $1.42. Bolstering investor confidence, ANI Pharmaceuticals increased its 2025 forecast, now expecting full-year revenues between $818 million and $843 million and adjusted earnings per share from $6.98 to $7.35, both well above prior guidance.

ANI Pharmaceuticals is up 7.7% since the beginning of the year, but at $84.43 per share, it is still trading 14.6% below its 52-week high of $98.81 from September 2025. Investors who bought $1,000 worth of ANI Pharmaceuticals’s shares 5 years ago would now be looking at an investment worth $2,642.

Wrapping up Q3 earnings, we look at the numbers and key takeaways for the pharmaceuticals stocks, including Jazz Pharmaceuticals and its peers.

The pharmaceuticals sector develops, manufactures, and distributes drugs, benefiting from diversified portfolios of branded and generic medications. Looking ahead, growth will be driven by innovations in precision medicine, such as genetic therapies and advanced biologics, and the increasing use of AI to speed and increase the efficiency of drug discovery. These could specifically magnify the advantages of the most scaled players. Conversely, the sector faces considerable headwinds from intense, bipartisan political pressure on drug pricing, scrutiny of patent practices, and growing competition from biosimilars. These could specifically stymie the growth of smaller companies or ones facing patent expirations on key drugs.

The 16 pharmaceuticals stocks we track reported a strong Q3. As a group, revenues beat analysts’ consensus estimates by 2.9% while next quarter’s revenue guidance was in line.

Luckily, pharmaceuticals stocks have performed well with share prices up 12.1% on average since the latest earnings results.

Jazz Pharmaceuticals

Originally founded in 2003 and now headquartered in Ireland following a 2012 tax inversion merger, Jazz Pharmaceuticals (NASDAQGS:JAZZ) develops and markets medicines for sleep disorders, epilepsy, and cancer, with a focus on treatments for patients with limited therapeutic options.

Jazz Pharmaceuticals reported revenues of $1.13 billion, up 6.7% year on year. This print exceeded analysts’ expectations by 1.1%. Overall, it was a very strong quarter for the company with a beat of analysts’ EPS estimates and a solid beat of analysts’ full-year EPS guidance estimates.

Interestingly, the stock is up 24.3% since reporting and currently trades at $170.53.

Best Q3: Eli Lilly

Founded in 1876 by a Civil War veteran and pharmacist frustrated with the poor quality of medicines, Eli Lilly discovers, develops, and manufactures pharmaceutical products for conditions including diabetes, obesity, cancer, immunological disorders, and neurological diseases.

Eli Lilly reported revenues of $17.6 billion, up 53.9% year on year, outperforming analysts’ expectations by 9.7%. The business had a stunning quarter with a solid beat of analysts’ revenue estimates and full-year revenue guidance exceeding analysts’ expectations.

Eli Lilly scored the fastest revenue growth among its peers. The market seems happy with the results as the stock is up 32.7% since reporting. It currently trades at $1,077.

Corcept

Focusing on the powerful stress hormone that affects everything from metabolism to immune function, Corcept Therapeutics develops and markets medications that modulate cortisol to treat endocrine disorders, cancer, and neurological diseases.

Corcept reported revenues of $207.6 million, up 13.7% year on year, falling short of analysts’ expectations by 4%. It was a softer quarter as it posted full-year revenue guidance missing analysts’ expectations significantly and a significant miss of analysts’ revenue estimates.

Corcept delivered the weakest performance against analyst estimates in the group. Interestingly, the stock is up 16% since the results and currently trades at $82.51.

Read our full analysis of Corcept’s results here.

ANI Pharmaceuticals

With a diverse portfolio of 116 pharmaceutical products and a growing rare disease platform, ANI Pharmaceuticals develops, manufactures, and markets branded and generic prescription pharmaceuticals, with a focus on rare disease treatments.

ANI Pharmaceuticals reported revenues of $227.8 million, up 53.6% year on year. This print surpassed analysts’ expectations by 6.4%. It was a very strong quarter as it also logged an impressive beat of analysts’ revenue estimates and a beat of analysts’ EPS estimates.

The stock is down 8.6% since reporting and currently trades at $82.49.

Read our full, actionable report on ANI Pharmaceuticals here, it’s free for active Edge members.

Merck

With roots dating back to 1891 and a portfolio that includes the blockbuster cancer immunotherapy Keytruda, Merck develops and sells prescription medicines, vaccines, and animal health products across oncology, infectious diseases, cardiovascular, and other therapeutic areas.

Merck reported revenues of $17.28 billion, up 3.7% year on year. This number beat analysts’ expectations by 1.8%. Overall, it was a strong quarter as it also produced an impressive beat of analysts’ constant currency revenue estimates and a beat of analysts’ EPS estimates.

The stock is up 23.5% since reporting and currently trades at $106.92.

Read our full, actionable report on Merck here, it’s free for active Edge members.